Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLINASDAQ:EYPTNASDAQ:OMIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLIBerkeley Lights$0.77$1.14▼$7.79$72.04M1.36845,024 shsN/AEYPTEyePoint Pharmaceuticals$9.03+1.9%$6.54$3.91▼$13.99$621.36M1.61819,335 shs822,461 shsOMICSingular Genomics Systems$20.01$20.01$5.34▼$23.41$50.83M1.8347,989 shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLIBerkeley Lights0.00%0.00%0.00%0.00%0.00%EYPTEyePoint Pharmaceuticals0.00%+1.01%+57.87%+38.50%-3.11%OMICSingular Genomics Systems0.00%0.00%0.00%0.00%+93.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLIBerkeley Lights0.8984 of 5 stars0.00.00.04.10.62.50.6EYPTEyePoint Pharmaceuticals2.1935 of 5 stars3.52.00.00.03.21.70.0OMICSingular Genomics SystemsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLIBerkeley Lights 0.00N/AN/AN/AEYPTEyePoint Pharmaceuticals 3.00Buy$25.38181.01% UpsideOMICSingular Genomics Systems 2.00Hold$6.50-67.52% DownsideCurrent Analyst Ratings BreakdownLatest EYPT, BLI, and OMIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025EYPTEyePoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.005/16/2025EYPTEyePoint PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.005/8/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $27.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLIBerkeley Lights$78.60M0.00N/AN/A$2.07 per share0.00EYPTEyePoint Pharmaceuticals$56.04M11.09N/AN/A$5.66 per share1.60OMICSingular Genomics Systems$2.91M17.47N/AN/A$73.25 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLIBerkeley Lights-$98.04M-$1.43N/AN/AN/A-124.74%-57.56%-39.40%N/AEYPTEyePoint Pharmaceuticals-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)OMICSingular Genomics Systems-$94.82M-$35.11N/A∞N/A-3,237.89%-57.87%-37.90%8/12/2025 (Estimated)Latest EYPT, BLI, and OMIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025EYPTEyePoint Pharmaceuticals-$0.65-$0.65N/A-$0.65$8.84 million$24.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLIBerkeley LightsN/AN/AN/AN/AN/AEYPTEyePoint PharmaceuticalsN/AN/AN/AN/AN/AOMICSingular Genomics SystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLIBerkeley Lights0.103.893.48EYPTEyePoint PharmaceuticalsN/A5.505.45OMICSingular Genomics Systems0.047.376.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLIBerkeley Lights68.43%EYPTEyePoint Pharmaceuticals99.41%OMICSingular Genomics Systems65.80%Insider OwnershipCompanyInsider OwnershipBLIBerkeley Lights17.60%EYPTEyePoint Pharmaceuticals4.46%OMICSingular Genomics Systems22.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLIBerkeley Lights29372.17 million59.47 millionNot OptionableEYPTEyePoint Pharmaceuticals12068.81 million65.02 millionOptionableOMICSingular Genomics Systems2202.54 million1.97 millionNo DataEYPT, BLI, and OMIC HeadlinesRecent News About These CompaniesSingular Genomics highlights G4X milestones at AGBTFebruary 24, 2025 | markets.businessinsider.comSingular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBTFebruary 24, 2025 | markets.businessinsider.comSingular Genomics announces closing of acquisition by Deerfield ManagmentFebruary 22, 2025 | markets.businessinsider.comSingular Genomics Shareholders Approve Merger AgreementFebruary 22, 2025 | investing.comSingular Genomics Systems, Inc. Closes Acquisition by Deerfield Management CompanyFebruary 21, 2025 | quiverquant.comSingular Genomics Announces Closing of Acquisition by Deerfield ManagementFebruary 21, 2025 | globenewswire.comSingular Genomics Systems IncFebruary 20, 2025 | morningstar.comAndrew Spaventa Sells 800 Shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) StockFebruary 15, 2025 | insidertrades.comSingular genomics CEO sells shares worth $15,912February 14, 2025 | msn.comSingular Genomics faces lawsuits over merger disclosuresFebruary 13, 2025 | msn.com(OMIC) Trading ReportFebruary 11, 2025 | news.stocktradersdaily.comGenomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Impacting Market Trends - TechnavioJanuary 31, 2025 | uk.finance.yahoo.comInvestors With Losses Are Invited To Join The Schall Law Firm In An Investigation Into Singular Genomics Systems, Inc. For Securities FraudJanuary 30, 2025 | accessnewswire.comSingular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach OutJanuary 29, 2025 | accessnewswire.comOMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law FirmJanuary 28, 2025 | prnewswire.comSingular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach OutJanuary 27, 2025 | accessnewswire.comInvestors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities FraudJanuary 26, 2025 | accessnewswire.comSingular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach OutJanuary 25, 2025 | accessnewswire.comInvestors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities FraudJanuary 24, 2025 | accessnewswire.comSingular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach OutJanuary 23, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBreakout Momentum Plays You May Not Know AboutBy Nathan Reiff | June 6, 2025View Breakout Momentum Plays You May Not Know AboutNVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?By Leo Miller | May 20, 2025View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?Viking Holdings Posts Strong Q1, Eyes Growth AheadBy Chris Markoch | May 20, 2025View Viking Holdings Posts Strong Q1, Eyes Growth AheadAmer Sports: The New ONON and DECK of Consumer Discretionary?By Leo Miller | May 28, 2025View Amer Sports: The New ONON and DECK of Consumer Discretionary?Buffett's Latest Portfolio Moves, and Another Secret StockBy Ryan Hasson | May 19, 2025View Buffett's Latest Portfolio Moves, and Another Secret StockEYPT, BLI, and OMIC Company DescriptionsBerkeley Lights NASDAQ:BLIBerkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. Berkeley Lights, Inc. was incorporated in 2011 and is headquartered in Emeryville, California.EyePoint Pharmaceuticals NASDAQ:EYPT$9.03 +0.17 (+1.92%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.04 +0.01 (+0.06%) As of 06/13/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Singular Genomics Systems NASDAQ:OMIC$20.01 0.00 (0.00%) As of 02/21/2025Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
